Small molecules play a key role in DMPK and bioanalysis, and are crucial to the discovery and developments of drugs. It is essential for scientists to develop more efficient, sensitive, robust and reliable methods and processes to qualitatively and quantitatively study small molecules. This is made possible with the help of cutting-edge emerging technologies, allowing scientists to keep up with the rapidly advancing area.
This panel discussion will provide insights into the challenges, trends, developments and debates surrounding DMPK and the bioanalysis of small molecules. With the help of leading experts we will explore key technologies that are evolving and why 48% of survey respondents believe that the percentage of small molecules analyzed will decrease in the next 5 years. If this is the case, what impact will this have on research, laboratories and the scientists involved?
What will you learn?
- What methods are used in the analysis of small molecules and why?
- The main challenges involved in the analysis of small molecules
- What the future holds for the analysis of small molecules
Principal Applications Chemist, Mass Spectrometry
Dan Weston has over 20 years experience in mass spectrometry, the majority of which has been gained using LC-MS/MS within the pharmaceutical industry, where he focused on metabolite characterisation for drug discovery (Schering-Plough, USA), drug development and human safety (AstraZeneca, UK). During this time, he also fostered successful collaborations and post-graduate research studentship for complex pharmaceutical analysis using high-resolution mass spectrometry with ion mobility and ambient ionisation techniques. Dan joined Waters in 2014 as a Principal Scientist in the European Applications Laboratory (Wilmslow, UK), where his main roles include driving scientific strategy and value-led collaborations, both across the Waters business and with key industrial peer-groups.
Senior Application Specialist
Sciex Application GroupsJason currently holds the position of Senior Application Specialist at SCIEX, concentrating on the Pharmaceutical and Bioanalytical markets within the UK & Europe. Jason is responsible for the development and implementation of analytical methods and workflows within this arena. He has experience in high-throughput method development, UHPLC-MS/MS applications & HRAMS, both within SCIEX and previously within the GLP environment.
Unilabs York Bioanalytical Solutions
Jan Boerma studied Pharmaceutical Sciences and completed his PhD in Molecular Toxicology at the VU University in Amsterdam (the Netherlands). His doctoral work focused on the use of Glutathione-S-Transferases as tools and targets for the characterisation of chemically resactive drug metabolites. Continuing his interest in drug metabolism he then joined Unilabs York Bioanalytical Solutions, a contract research organisation, in Sandwich (UK) as a Biotransformation Scientist. He is currently performing metabolism studies in support of discovery (e.g. soft spot analysis) and development projects (e.g. radiolabelled ADME and MIST studies).
Sr. Director of DMPK
Larry Jolivette is Head of the Future Pipeline Discovery DMPK Core at GlaxoSmithKline (GSK). The group supports discovery efforts for CNS, muscle, liver, kidney, cardiac and infectious disease indications. He is active on several DMPK-related advisory and matrix teams within GSK including the DMPK Council (treasurer), the Biotransformation Advisory Team, the Analytical Sciences Steering Team, the DMPK Review Forum, the Human Dose Prediction Review Panel and the Quantitative Pharmacology Community of Practice Steering Team. Larry joined GSK in 2001 after earning degrees in Chemistry (BS) from Southern University (LA, USA) and in Pharmacology (PhD) from the University of Rochester (NY, USA).